{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:15:35Z","timestamp":1792419335306,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2023, non-alcoholic fatty liver disease (NAFLD) was defined as metabolic dysfunction-associated steatotic liver disease (MASLD) to avoid stigmatizing terminology. Although recent studies have suggested an association between MASLD and serum uric acid (SUA), the evidence remains limited. In this study, we aimed to assess the association between MASLD and SUA in Japanese participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 3,264 eligible participants (1,917 men and 1,347 women) who underwent voluntary health checkups at Juntendo University Hospital, Tokyo, Japan, between January 2021 and December 2023. Data on basic characteristics, anthropometric indices, blood pressure, glycemic and lipid markers, SUA levels, and medical histories were collected. Steatosis was assessed by computed tomography or ultrasound. MASLD was defined as imaging-confirmed steatosis plus at least one metabolic dysfunction criterion. The participants were stratified into sex-specific SUA quartiles. Associations between MASLD and SUA quartiles were evaluated by multivariable logistic and Poisson regression, adjusted for age, alcohol consumption, smoking, estimated glomerular filtration rate, urate-lowering medication use, and body mass index. The results are reported as adjusted odds ratios (AORs) or prevalence ratios (PRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Higher SUA levels were significantly associated with MASLD prevalence. After adjustment for confounders, the association remained significant. Compared with the lowest quartile, the AORs (95% CI) for MASLD in men were: Q2, 1.45 (1.08\u20131.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01); Q3, 1.43 (1.04\u20131.95,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01); and Q4, 2.00 (1.45\u20132.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). In women, the AORs were: Q2, 1.45 (0.90\u20132.35,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.13); Q3, 2.21 (1.39\u20133.53,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01); and Q4, 3.52 (2.22\u20135.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). SUA that was treated as a continuous variable showed a clear dose\u2013response association in both sexes. Sensitivity analyses using imaging-defined steatosis yielded consistent results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SUA levels were positively associated with MASLD in both men and women, with women showing elevated MASLD risk even at SUA levels below the conventional hyperuricemia threshold. SUA might serve as a clinically relevant metabolic indicator; consideration of sex-specific metabolic risk might improve MASLD risk assessment. Further research on clarifying causal pathways is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-026-02174-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:04:44Z","timestamp":1769749484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Positive association between serum uric acid and metabolic dysfunction-associated steatotic liver disease: insights from a Japanese health checkup cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Mari","family":"Arikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizue","family":"Saita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohide","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2174_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103:e1\u201313. https:\/\/doi.org\/10.1097\/TP.0000000000002480.","journal-title":"Transplantation"},{"key":"2174_CR2","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9\u201319.","journal-title":"Hippokratia"},{"key":"2174_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.12229","volume":"16","author":"S O\u2019Neill","year":"2015","unstructured":"O\u2019Neill S, O\u2019Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1\u201312. https:\/\/doi.org\/10.1111\/obr.12229.","journal-title":"Obes Rev"},{"key":"2174_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04724.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2174_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 and 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586\u201395. https:\/\/doi.org\/10.1007\/s00535-012-0533-z.","journal-title":"J Gastroenterol"},{"key":"2174_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","volume":"143","author":"M Hamaguchi","year":"2005","unstructured":"Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722\u20138. https:\/\/doi.org\/10.7326\/0003-4819-143-10-200511150-00009.","journal-title":"Ann Intern Med"},{"key":"2174_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"2174_CR8","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.3390\/ijms242015473","volume":"24","author":"H Yanai","year":"2023","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci. 2023;24:15473. https:\/\/doi.org\/10.3390\/ijms242015473.","journal-title":"Int J Mol Sci"},{"key":"2174_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811\u201321. https:\/\/doi.org\/10.1056\/NEJMra0800885.","journal-title":"N Engl J Med"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jch.12627","volume":"18","author":"H Yokokawa","year":"2016","unstructured":"Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, et al. Association between serum uric acid levels\/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens (Greenwich). 2016;18:53\u20139. https:\/\/doi.org\/10.1111\/jch.12627.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2174_CR11","first-page":"136","volume":"49","author":"G Darmawan","year":"2017","unstructured":"Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49:136\u201347.","journal-title":"Acta Med Indones"},{"key":"2174_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/BF00296994","volume":"30","author":"M Modan","year":"1987","unstructured":"Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid\u2014a facet of hyperinsulinaemia. Diabetologia. 1987;30:713\u20138. https:\/\/doi.org\/10.1007\/BF00296994.","journal-title":"Diabetologia"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1001\/jama.1991.03470210076036","volume":"266","author":"F Facchini","year":"1991","unstructured":"Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008\u201311.","journal-title":"JAMA"},{"key":"2174_CR14","doi-asserted-by":"publisher","first-page":"e144762","DOI":"10.1172\/jci.insight.144762","volume":"6","author":"Y Kawachi","year":"2021","unstructured":"Kawachi Y, Fujishima Y, Nishizawa H, Nakamura T, Akari S, Murase T, et al. Increased plasma XOR activity induced by NAFLD\/NASH and its possible involvement in vascular neointimal proliferation. JCI Insight. 2021;6:e144762. https:\/\/doi.org\/10.1172\/jci.insight.144762.","journal-title":"JCI Insight"},{"key":"2174_CR15","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.jhep.2023.12.009","volume":"80","author":"L He","year":"2024","unstructured":"He L, Qiu K, Zheng W, Kong W, Zeng T. Uric acid May serve as the sixth cardiometabolic criterion for defining MASLD. J Hepatol. 2024;80:e152\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2023.12.009.","journal-title":"J Hepatol"},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12876-025-03666-9","volume":"25","author":"Z Chang","year":"2025","unstructured":"Chang Z, Liu Z. Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort. BMC Gastroenterol. 2025;25:94. https:\/\/doi.org\/10.1186\/s12876-025-03666-9.","journal-title":"BMC Gastroenterol"},{"key":"2174_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12889-024-21214-0","volume":"25","author":"D Shi","year":"2025","unstructured":"Shi D, Tan Q, Zhang Y, Qi X, Xu X, Xu G, et al. Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in china: a 2019\u20132021 cohort health survey. BMC Public Health. 2025;25:653. https:\/\/doi.org\/10.1186\/s12889-024-21214-0.","journal-title":"BMC Public Health"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1507\/endocrj.EJ24-0622","volume":"72","author":"T Fukuda","year":"2025","unstructured":"Fukuda T, Akihisa T, Okamoto T, Fukaishi T, Kawakami A, Tanaka M, et al. Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related\/associated steatotic liver disease: a study on Japanese participants undergoing health checkups. Endocr J. 2025;72:671\u201387. https:\/\/doi.org\/10.1507\/endocrj.EJ24-0622.","journal-title":"Endocr J"},{"key":"2174_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0091-7435(72)90014-x","volume":"1","author":"NB Belloc","year":"1972","unstructured":"Belloc NB, Breslow L. Relationship of physical health status and health practices. Prev Med. 1972;1:409\u201321. https:\/\/doi.org\/10.1016\/0091-7435(72)90014-x.","journal-title":"Prev Med"},{"issue":"1","key":"2174_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14867\/gnamtsunyo.46.1_15","volume":"46","author":"N Haruhara","year":"2022","unstructured":"Haruhara N, Satoh N, Mukai M, Nishi T. Examination of sex differences in excretion of uric acid. Gout Uric Nucleic Acids. 2022;46(1):15\u201322. https:\/\/doi.org\/10.14867\/gnamtsunyo.46.1_15. (in Japanese with English abstract).","journal-title":"Gout Uric Nucleic Acids"},{"key":"2174_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ard.2009.109884","volume":"69","author":"AE Hak","year":"2010","unstructured":"Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305\u20139. https:\/\/doi.org\/10.1136\/ard.2009.109884.","journal-title":"Ann Rheum Dis"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jjcc.2020.01.011","volume":"76","author":"S Tani","year":"2020","unstructured":"Tani S, Matsuo R, Imatake K, Suzuki Y, Takahashi A, Yagi T, et al. The serum uric acid level in females May be a better indicator of metabolic syndrome and its components than in males in a Japanese population. J Cardiol. 2020;76:100\u20138. https:\/\/doi.org\/10.1016\/j.jjcc.2020.01.011.","journal-title":"J Cardiol"},{"key":"2174_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","volume":"80","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694\u2013701. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.014.","journal-title":"J Hepatol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02174-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:22:39Z","timestamp":1781630559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02174-5","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and Ethical Guidelines for Medical Research Involving Human Subjects in Japan. The research protocol was reviewed and approved by the Ethics Committee of Juntendo University (approval number: E23-0431). Written informed consent was obtained from all participants at the time of their health checkup.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}